>> LIVE FROM WASHINGTON, D.C., THIS IS "BALANCE OF POWER," WITH JOE MATHIEU AND KAILEY LEINZ. JOE: PRESIDENT TRUMP SUPPORTIVE PIECE HOLDS ITS FIRST MEETING EVEN AS HE ASSEMBLES THE BIGGEST MILITARY BUILDUP SINCE THE INVASION OF IRAQ IN 2003. THAT HAPPENING AS WE SPEAK IN THE MIDDLE EAST. I'M JOE MATHIEU ALONGSIDE KAILEY LEINZ IN WASHINGTON. THANK YOU FOR BEING HERE ONE OF US FRIDAY EDITION. THE PRESIDENT PIVOTS TO AFFORDABILITY. KAILEY: TWO AREAS OF FOCUS. ONE ABROAD AND ONE HERE AT HOME, WHERE HIS CHIEF OF ...

And right now we are 2 minutes away from the end of the trading day. Romaine Bostick alongside Katie Graham Bell taking you through to that closing bell with a global simulcast. Carol Massar and Tim Stenovec join us right now.Welcome to our audiences across all of our bloomberg platforms, television, radio. Our partnership with youtube, a bit of a flip flop from what we saw yesterday. Carol Massar With stocks on the back foot, though, some of this seems to be tied to fears about what might be going on over ...

Core Viewpoint - A class action lawsuit has been filed against Klarna Group plc for allegedly misleading investors regarding the company's financial health and risk disclosures related to its IPO [8]. Allegation Details - The lawsuit claims that Klarna's Registration Statement contained false and misleading statements, particularly regarding the risk of increased loss reserves shortly after the IPO [8]. - It is alleged that the defendants either knew or should have known about the risk profile of individuals taking Klarna's buy now, pay later loans, which was not adequately disclosed [8]. Financial Impact - Klarna launched its IPO on September 10, 2025, selling 34,311,274 shares at $40.00 each [8]. - Following the announcement of disappointing Q3 2025 financial results on November 18, 2025, which included a significant increase in credit loss provisions, Klarna's share price fell by $3.25, or approximately 9.3%, from $34.88 to $31.63 [8]. Next Steps for Investors - Investors who purchased Klarna shares and suffered losses are encouraged to contact the law firm Bragar Eagel & Squire for more information and to discuss their legal rights [4].

Walmart, Occidental, Klarna, Wayfair, Deere, Omnicom, and More Stock Movers - Barron'sSkip to Main ContentThis copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order multiple copies, please contact Dow Jones Reprints at 1-800-843-0008 or visit www.djreprints.com.# These Stocks Are Today's Movers: Walmart, Occidental, Klarna, Wayfair, Deere, Omnicom, EPAM, and MoreBy [Mackenzie T ...

SAN FRANCISCO, Feb. 19, 2026 (GLOBE NEWSWIRE) -- National shareholder rights law firm Hagens Berman is notifying investors in Klarna Group plc (NYSE: KLAR) of the upcoming February 20, 2026, lead plaintiff deadline in a pending securities class action. The firm is actively investigating the lawsuit’s claims of alleged misstatements in Klarna’s September 2025 Initial Public Offering (IPO) documents. CLICK HERE TO SUBMIT YOUR KLARNA LOSSES Investors who purchased Klarna (KLAR) shares pursuant to the company’s ...

Klarna (KLAR) shares closed roughly 26% down on Thursday even though the buy now, pay later (BNPL) firm posted its first billion-dollar quarter. Investors bailed on KLAR mostly because its profitability metrics deteriorated in the fourth quarter and the management offered disappointing guidance for Q1. Following the post-earnings decline, Klarna’s relative strength index (14-day) sits at about 18.39, indicating extremely oversold conditions that often trigger a relief rally. More News from Barchart How ...

Klarna Gets Crushed After Revenue Win Runs Foul - Moby BREAKING NEWS Klarna is getting punished by Wall Street today after the payments company reported Q4 earnings that missed profitability expectations but nailed revenue. KLAR is down 26.5% at the time of writing, trading at lows of $13.9 after highs of $58. The brutal drop comes after their first $1 billion-dollar revenue quarter, coming in at $1.082 billion, up 38% year-over-year (58% in the U.S.). Gross merchandise volume (GMV) also did well, risi ...

The strategic shift positions Klarna less as an installment lender and more as a multi-product financial network monetizing cross-sell dynamic.Klarna’s earnings highlight a banking flywheel where checkout activity, cards and deposits reinforce one another.Klarna’s fourth-quarter results offer a snapshot into the appeal of paying over time. They also provide a window into the mechanics of a rapidly scaling financial network, where checkout activity, cards and deposits increasingly reinforce one another.By co ...

Klarna Group PLC's (NYSE:KLAR) "buy now, pay later" promise is colliding with a harsh public-market reality. Just months after its 2025 IPO, Klarna reported its first billion-dollar revenue quarter — but investors focused on the losses. Revenue surged 38% year-over-year to $1.08 billion, beating expectations, yet the company swung to a $26 million quarterly loss and issued weaker-than-expected guidance, triggering a sharp stock selloff.The earnings shock comes as Klarna faces mounting legal pressure, with F ...

Group 1 - The law firm Faruqi & Faruqi, LLP is investigating potential claims against REGENXBIO Inc. related to a federal securities class action due to alleged violations of federal securities laws [1] - The complaint alleges that REGENXBIO and its executives made false or misleading statements and failed to disclose material adverse facts regarding the efficacy and safety of its RGX-111 trial study [1] - On January 28, 2026, REGENXBIO announced that the FDA placed a clinical hold on its RGX-111 investigational gene therapy for MPS I after a case of neoplasm was reported in a participant [1] - The FDA also placed a clinical hold on RGX-121 for MPS II, citing similarities in products and shared risks between the clinical studies [1] - Following the FDA's announcement, REGENXBIO's stock price fell by $2.40 per share, or 17.9%, closing at $11.01 per share [1] Group 2 - The deadline for investors to seek the role of lead plaintiff in the class action is April 14, 2026 [1] - Any member of the putative class can move the Court to serve as lead plaintiff or remain an absent class member without affecting their ability to share in any recovery [1] - Faruqi & Faruqi encourages individuals with information regarding REGENXBIO's conduct to contact the firm, including whistleblowers and former employees [1]